Podoplanin-Positive Cancer-Associated Fibroblasts in the Tumor Microenvironment Induce Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma with EGFR Mutation

被引:96
|
作者
Yoshida, Tatsuya [1 ,2 ,3 ]
Ishii, Genichiro [1 ]
Goto, Koichi [2 ]
Neri, Shinya [1 ]
Hashimoto, Hiroko [1 ]
Yoh, Kiyotaka [2 ]
Niho, Seiji [2 ]
Umemura, Shigeki [2 ]
Matsumoto, Shingo [2 ]
Ohmatsu, Hironobu [2 ]
Iida, Shinsuke [3 ]
Niimi, Akio [3 ]
Nagai, Kanji [2 ]
Ohe, Yuichiro [2 ]
Ochiai, Atsushi [1 ]
机构
[1] Natl Canc Ctr Hosp East, Div Pathol, Res Ctr Innovat Oncol, Kashiwa, Chiba 2778577, Japan
[2] Natl Canc Ctr Hosp East, Div Thorac Oncol, Kashiwa, Chiba 2778577, Japan
[3] Nagoya City Univ, Grad Sch Med Sci, Dept Med Oncol & Immunol, Nagoya, Aichi, Japan
关键词
TYROSINE KINASE INHIBITORS; PREDICTS POOR-PROGNOSIS; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; OPEN-LABEL; GEFITINIB; GROWTH; CHEMOTHERAPY; STROMA; POLYMORPHISM;
D O I
10.1158/1078-0432.CCR-14-0846
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The biologic characteristics of microenvironmental constituents, especially cancer-associated fibroblasts (CAF), can be key regulators of the cellular sensitivity to molecular-targeted therapy. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) have marked therapeutic effects against non-small cell lung cancer (NSCLC) with EGFR mutations, but some patients have exhibited primary resistance to EGFR-TKIs. We recently reported that podoplanin-positive fibroblasts are associated with a tumor-promoting phenotype of CAFs in lung adenocarcinoma. The aim of this study was to evaluate whether the susceptibility of NSCLC to EGFR-TKIs could be affected by podoplanin-expressing CAFs. Experimental Design: We evaluated the EGFR-TKI sensitivity of EGFR-mutant lung adenocarcinoma cell lines cocultured with podoplanin-expressing CAFs. We also examined the association between the expression of podoplanin in CAFs in surgical specimens and EGFR-TKI response of postoperative recurrent patients with EGFR mutations (N = 106). Results: Lung adenocarcinoma cell lines became more resistant to EGFR-TKI when cocultured with podoplanin-expressing CAFs, compared with control CAFs in vitro. The knockdown of podoplanin expression on CAFs cancelled the resistance to EGFR-TKIs in cancer cells. Compared with control CAFs, the cancer cells that were cocultured with podoplanin-positive CAFs continued to exhibit significantly higher p-ERK levels after treatment with gefitinib. Furthermore, postoperative recurrent patients with podoplanin-positive CAFs had a significantly lower overall response rate to EGFR-TKIs compared with those with podoplanin-negative CAFs (53% vs. 83%; P < 0.01). Conclusions: Podoplanin-positive CAFs play an important role in primary resistance to EGFR-TKIs and may be an ideal therapeutic target for use in combination therapy with EGFR-TKIs. (C) 2014 AACR.
引用
收藏
页码:642 / 651
页数:10
相关论文
共 50 条
  • [1] The influence of tumor heterogeneity on sensitivity of EGFR-mutant lung adenocarcinoma cells to EGFR-TKIs
    Sun, Li
    Li, Yao-Yong
    Ma, Jie-Tao
    Zhang, Shu-Ling
    Huang, Le-Tian
    Han, Cheng-Bo
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 (05) : 1834 - 1844
  • [2] Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations
    Wang, Fang
    Diao, Xia-Yao
    Zhang, Xiao
    Shao, Qiong
    Feng, Yan-Fen
    An, Xin
    Wang, Hai-Yun
    CANCER COMMUNICATIONS, 2019, 39
  • [3] Use of iTRAQ to discover serum proteins associated with acquired EGFR-TKIs resistance in patients with advanced lung adenocarcinoma
    Xu, Yufen
    Chen, Wenyu
    Li, Xia
    Jiang, Yiming
    Song, Binbin
    Zhou, Qiang
    Wang, Aifen
    Wang, Yajuan
    Yang, Xinmei
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2017, 10 (04): : 4210 - 4220
  • [4] Genomic characteristics of PD-L1-Induced resistance to EGFR-TKIs in lung adenocarcinoma
    Yi, Guangming
    Cai, Fanghao
    Liu, Liangzhong
    Liao, Rongxin
    Jiang, Xuan
    Yang, Zhenzhou
    Zhang, Xiaoyue
    FUTURE ONCOLOGY, 2024, 20 (40) : 3477 - 3490
  • [5] Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer
    Zhou, Jia-Ying
    Liu, Si-Yang
    Wu, Yi-Long
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (05) : 589 - 599
  • [6] Cancer-Associated Fibroblasts Derived from EGFR-TKI-Resistant Tumors Reverse EGFR Pathway Inhibition by EGFR-TKIs
    Mink, Sheldon R.
    Vashistha, Surabhi
    Zhang, Wenxuan
    Hodge, Amanda
    Agus, David B.
    Jain, Anjali
    MOLECULAR CANCER RESEARCH, 2010, 8 (06) : 809 - 820
  • [7] Podoplanin-positive cancer-associated fibroblasts predict poor prognosis in lung cancer patients
    Hu, Guoming
    Zhong, Kefang
    Chen, Wei
    Wang, Shimin
    Huang, Liming
    ONCOTARGETS AND THERAPY, 2018, 11 : 5607 - 5619
  • [8] High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naive advanced EGFR-mutant lung adenocarcinoma patients
    Hsu, Kuo-Hsuan
    Huang, Yen-Hsiang
    Tseng, Jeng-Sen
    Chen, Kun-Chieh
    Ku, Wen-Hui
    Su, Kang-Yi
    Chen, Jeremy J. W.
    Chen, Huei-Wen
    Yu, Sung-Liang
    Yang, Tsung-Ying
    Chang, Gee-Chen
    LUNG CANCER, 2019, 127 : 37 - 43
  • [9] Podoplanin-Positive Fibroblasts Enhance Lung Adenocarcinoma Tumor Formation: Podoplanin in Fibroblast Functions for Tumor Progression
    Hoshino, Ayuko
    Ishii, Genichiro
    Ito, Takashi
    Aoyagi, Kazuhiko
    Ohtaki, Yoichi
    Nagai, Kanji
    Sasaki, Hiroki
    Ochiai, Atsushi
    CANCER RESEARCH, 2011, 71 (14) : 4769 - 4779
  • [10] The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer
    Bai, Hao
    Xiong, Liwen
    Han, Baohui
    ONCOTARGETS AND THERAPY, 2017, 10 : 2335 - 2340